Long‐term Follow‐up of the “Wait and See” Approach to Localized Perinatal Adrenal Neuroblastoma

Cozzi, Denis A.; Mele, Ermelinda; Ceccanti, Silvia; Natale, Fabio; Clerico, Aldo; Schiavetti, Amalia; Dominici, Carlo

doi:10.1007/s00268-012-1837-0

Cited by 35 publications

(25 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Long-term follow-up for these survivors, including monitoring for complications, has become an important issue (6)(7)(8). However, it is known that neuroblastoma with favorable biology often undergoes spontaneous regression and maturation, and these are associated with factors such as the age at diagnosis and the treatment administered (9,10). In several recent studies, observation programs for low-risk neuroblastoma were enforced expecting tumor regression or maturation (10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

“…However, it is known that neuroblastoma with favorable biology often undergoes spontaneous regression and maturation, and these are associated with factors such as the age at diagnosis and the treatment administered (9,10). In several recent studies, observation programs for low-risk neuroblastoma were enforced expecting tumor regression or maturation (10)(11)(12). Furthermore, it has been known that neuroblastoma cells show differentiation or necrosis following the administration of chemotherapeutic agents (13).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis

Iehara

Yagyu

Tsuchiya

et al. 2016

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Background: It remains unclear whether a residual tumor mass following therapy influences the prognosis of neuroblastoma. Methods: We retrospectively reviewed 20 patients with intermediate-risk tumors treated at our institution between 1993 and 2012 to elucidate whether additional treatment is required for residual tumors. Results: The patient ages at diagnosis ranged from 0 days to 7 years. The 5-year overall survival rate was 94.4%. Thirteen patients had Stage 3 disease and seven patients had Stage 4 disease. Nine patients showed intraspinal extension. Twelve patients had a residual tumor mass at the completion of therapy, and eight showed intraspinal extension. Five of these 12 patients showed metaiodobenzylguanidine (MIBG) uptake at the end of treatment, but the uptake disappeared during the follow-up period. Except for one patient who died due to treatment complications, the rest are all alive, and nine are alive with a residual mass. We examined the residual mass in four patients and found that these tissues had differentiated into a ganglioneuroma or changed to a necrotic tissue. For the three patients with neurological symptoms at the end of treatment, some slight neurological symptoms still remained during the follow-up. Five patients with an intraspinal mass eventually presented with new symptoms. Conclusions: The presence of a residual mass at the end of treatment did not influence the patients' prognosis. Therefore, an invasive radical surgical resection and additional treatment may not be necessary. Cases with a residual intraspinal mass also require a long-term follow-up to assess the neurological prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis

Iehara

Yagyu

Tsuchiya

et al. 2016

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Клинически нейробластома -чрезвычайно гетерогенная опухоль -может спонтанно рег-рессировать или созревать без лечения [4,5], что позволяет занять выжидательную позицию (стратегия «see and wait») 1 [6,7]. Однако возмож-ны агрессивное течение и резистентность к совре-менной интенсивной мультимодальной терапии [8].…”

Section: обоснованиеunclassified

Treatment of High-Risk Neuroblastoma

Хижников¹,

Казанцев²

2017

Oncopediatria

View full text Add to dashboard Cite

show abstract

“…Консервативная тактика при веде-нии детей с КН общепризнана [12]. Нейробластома, диагностированная в перинатальном периоде, вклю-чая кистозные формы ВН, отличается благоприятны-ми биологическими характеристиками, включающими низкую частоту встречаемости амплификации прото-онкогена MYCN и других неблагоприятных молекуляр-но-генетических аберраций, триплоидный набор хро-мосом (ДНК-индекс > 1) [13].…”

Section: обсуждение результатов исследованияunclassified

Di erential diagnosis of congenital cystic neuroblastoma and prenatal adrenal hemorrhage in children of the rst months of life

Феоктистова¹,

Ускова²,

Varfolomeeva³

et al. 2017

VGOIP

View full text Add to dashboard Cite

Вопросы гематологии/онкологии и иммунопатологии в педиатрии № Дифференциальная диагностика объемных образований в проекции надпочечников у ново-рожденных детей и детей первых месяцев жизни -чрезвычайно сложная клиническая задача. В данном случае чаще всего речь идет о врожденных кистозных нейробластомах и кровоизлияни-ях в надпочечник. Как правило, отсутствие клинической симптоматики и схожесть данных визу-ализации не позволяют четко дифференцировать данные патологические состояния, в связи с этим во многих случаях методом выбора становится оперативное удаление образования с после-дующей гистологической верификацией. Однако все больше исследователей высказывают мне-ние о том, что необходимо придерживаться консервативно-выжидательной тактики в отношении детей первых месяцев жизни. В статье представлен случай наблюдения за пациентом с образо-ванием надпочечника, описаны трудности, с которыми столкнулись авторы при постановке окон-чательного клинического диагноза. Differential diagnosis of adrenal gland tumor in neonates and children of the first months of life is an extremely difficult clinical task. Most often, it is congenital cystic neuroblastoma or prenatal adrenal hemorrhage. As a rule, it is hard to make the right diagnosis due to absence of clinical presentation and similarity of visualization data therefore sometimes surgical tumor removal followed by histological verification becomes the method of choice. The article presents a clinical case of the adrenal gland tumor in 5-months old boy. Authors discuss the difficulties in the formulation of the final clinical diagnosis.

show abstract

Long‐term Follow‐up of the “Wait and See” Approach to Localized Perinatal Adrenal Neuroblastoma

Cited by 35 publications

References 40 publications

Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis

Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis

Treatment of High-Risk Neuroblastoma

Di erential diagnosis of congenital cystic neuroblastoma and prenatal adrenal hemorrhage in children of the rst months of life

Contact Info

Product

Resources

About